For example, Herceptin is used in patients with female breast cancer with HER-2 expression, Imatinib targets the BCR/ABL fusion gene in chronic myeloid leukemia, Vemurafenib targets BRAF mutations in melanoma, and Gleevec inhibits tyrosine kinase activity in chronic myeloid leukemias. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.